Form 4: Corbus Pharma Director Receives Equity Grant

Corbus Pharmaceuticals director Anne Altmeyer was granted 3,800 restricted stock units and 12,300 stock options, vesting in one year.

Summary

• Anne Altmeyer, a Director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), received an equity grant.
• The grant, dated May 19, 2026, included 3,800 restricted stock units (RSUs) and 12,300 stock options.
• The RSUs were granted at a price of $0.
• The stock options have an exercise price of $9.15.
• Both the RSUs and stock options will vest 100% on the one-year anniversary of the grant date, which is May 19, 2027.
• Following these transactions, Anne Altmeyer beneficially owns 9,991 shares of common stock (which includes 8,600 previously reported unvested RSUs) and 12,300 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine director compensation and alignment of interests, without significant new information on company performance.

Positives

• The grant of equity to a director aligns management interests with shareholder value, incentivizing long-term performance.
• The stock options were awarded under the issuer's 2024 Equity Compensation Plan, indicating a structured and approved approach to executive compensation.

Future Outlook

The filing indicates future vesting of equity awards for a director, aligning their long-term incentives with the company's performance over the next year.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and pharmaceutical industry, aiming to incentivize long-term commitment and align leadership interests with shareholder returns. This grant is consistent with typical compensation structures for non-executive directors in the sector.

Comparison to Industry Standards

• Equity grants to directors are a common compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of one year is typical for such grants, encouraging retention and long-term focus.
• The specific number of units and options granted would need to be compared against peer companies of similar market capitalization and stage of development to assess if it's within industry norms, but the filing itself does not provide this comparative data.

Corporate Governance

Related Party Transactions

• The equity grant to Anne Altmeyer, a director, constitutes a related party transaction, which is a standard compensation practice disclosed via Form 4.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with shareholder value through equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The granted RSUs and stock options will vest 100% on May 19, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice and does not provide new information significant enough to alter an investment thesis. It reinforces alignment of interests but does not indicate a change in the company's fundamental outlook or performance.

Keywords

Corbus Pharmaceuticals, CRBP, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation